Eversept Partners, LP Affimed N.V. Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Nov 08, 2023	SELL	$0.57 - $1.08 $118,046 - $223,668	-207,100 Reduced 10.99%	1,676,684 $1.01 Million
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $118,046 - $223,668	-207,100 Reduced 10.99%	1,676,684 $1.01 Million
Q1 2023 Nov 08, 2023	BUY	$0.66 - $1.29 $1.03 Million - $2 Million	1,553,560 Added 470.46%	1,883,784 $1.41 Million
Q1 2023 May 15, 2023	BUY	$0.66 - $1.29 $1.03 Million - $2 Million	1,553,560 Added 470.46%	1,883,784 $1.41 Million
Q4 2022 Nov 08, 2023	SELL	$1.1 - $2.45 $1.71 Million - $3.82 Million	-1,557,775 Reduced 82.51%	330,224 $409,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $1.71 Million - $3.82 Million	-1,557,775 Reduced 82.51%	330,224 $409,000
Q3 2022 Nov 08, 2023	BUY	$1.96 - $3.32 $1.48 Million - $2.51 Million	757,238 Added 66.97%	1,887,999 $3.89 Million
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $1.48 Million - $2.51 Million	757,238 Added 66.97%	1,887,999 $3.89 Million
Q2 2022 Nov 08, 2023	SELL	$2.27 - $4.86 $1.24 Million - $2.65 Million	-545,923 Reduced 32.56%	1,130,761 $3.13 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $2.57 Million - $5.5 Million	1,130,761 New	1,130,761 $3.13 Million
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $3.14 Million - $4.26 Million	-566,942 Closed	0 $0
Q2 2021 Nov 08, 2023	SELL	$7.78 - $11.4 $3.73 Million - $5.46 Million	-479,187 Reduced 45.81%	566,942 $4.82 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $3.73 Million - $5.46 Million	-479,187 Reduced 45.81%	566,942 $4.82 Million
Q1 2021 Nov 08, 2023	BUY	$5.12 - $8.48 $416,880 - $690,458	81,422 Added 8.44%	1,046,129 $8.27 Million
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $416,880 - $690,458	81,422 Added 8.44%	1,046,129 $8.28 Million
Q4 2020 Nov 08, 2023	SELL	$3.16 - $7.03 $2.25 Million - $5.01 Million	-711,977 Reduced 42.46%	964,707 $5.61 Million
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $887,173 - $1.97 Million	-280,751 Reduced 22.54%	964,707 $5.62 Million
Q3 2020 Nov 08, 2023	BUY	$3.26 - $4.73 $986,048 - $1.43 Million	302,469 Added 32.08%	1,245,458 $4.22 Million
Q3 2020 Nov 13, 2020	BUY	$3.26 - $4.73 $986,048 - $1.43 Million	302,469 Added 32.08%	1,245,458 $4.22 Million
Q2 2020 Nov 08, 2023	BUY	$1.58 - $4.63 $603,858 - $1.77 Million	382,189 Added 68.15%	942,989 $4.36 Million
Q2 2020 Aug 13, 2020	BUY	$1.58 - $4.63 $603,858 - $1.77 Million	382,189 Added 68.15%	942,989 $4.35 Million
Q1 2020 Nov 08, 2023	SELL	$1.44 - $3.02 $427,638 - $896,852	-296,971 Reduced 34.62%	560,800 $886,000
Q1 2020 May 13, 2020	SELL	$1.44 - $3.02 $427,638 - $896,852	-296,971 Reduced 34.62%	560,800 $886,000
Q4 2019 Nov 08, 2023	BUY	$2.25 - $3.07 $1.21 Million - $1.64 Million	535,600 Added 166.25%	857,771 $2.35 Million
Q4 2019 Feb 13, 2020	BUY	$2.25 - $3.07 $1.21 Million - $1.64 Million	535,600 Added 166.25%	857,771 $2.35 Million
Q1 2019 Nov 08, 2023	SELL	$3.05 - $4.34 $41,489 - $59,037	-13,603 Reduced 4.05%	322,171 $1.35 Million
Q1 2019 May 14, 2019	SELL	$3.05 - $4.34 $41,489 - $59,037	-13,603 Reduced 4.05%	322,171 $1.35 Million
Q4 2018 Nov 08, 2023	SELL	$2.82 - $4.67 $273,407 - $452,770	-96,953 Reduced 22.41%	335,774 $1.04 Million
Q4 2018 Feb 13, 2019	SELL	$2.82 - $4.67 $273,407 - $452,770	-96,953 Reduced 22.41%	335,774 $1.04 Million
Q3 2018 Nov 08, 2023	BUY	$1.45 - $6.15 $66,504 - $282,069	45,865 Added 11.86%	432,727 $1.88 Million
Q3 2018 Nov 14, 2018	BUY	$1.45 - $6.15 $66,504 - $282,069	45,865 Added 11.86%	432,727 $1.88 Million
Q1 2018 Nov 08, 2023	SELL	$1.25 - $2.65 $1.61 Million - $3.42 Million	-1,289,822 Reduced 76.93%	386,862 $716 Million
Q1 2018 May 14, 2018	BUY	$1.25 - $2.65 $483,577 - $1.03 Million	386,862 New	386,862 $716,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account